Truist Financial Corp Acquires Shares of 17,703 Artivion, Inc. $AORT

Truist Financial Corp acquired a new stake in Artivion, Inc. (NYSE:AORT - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 17,703 shares of the company's stock, valued at approximately $551,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Legacy Advisors LLC acquired a new stake in Artivion in the first quarter valued at approximately $28,000. MCF Advisors LLC grew its stake in Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after acquiring an additional 614 shares during the period. EntryPoint Capital LLC acquired a new stake in Artivion in the first quarter valued at approximately $284,000. Natixis Advisors LLC boosted its position in shares of Artivion by 16.4% during the first quarter. Natixis Advisors LLC now owns 12,615 shares of the company's stock valued at $310,000 after buying an additional 1,777 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Artivion by 18.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,358 shares of the company's stock valued at $353,000 after buying an additional 2,285 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.

Analysts Set New Price Targets

AORT has been the topic of several analyst reports. Canaccord Genuity Group lifted their target price on Artivion from $41.00 to $50.00 and gave the company a "buy" rating in a research report on Monday, September 29th. Wall Street Zen raised Artivion from a "hold" rating to a "buy" rating in a research report on Monday, August 25th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Artivion in a research report on Wednesday, October 8th. Stifel Nicolaus lifted their target price on Artivion from $40.00 to $46.00 and gave the company a "buy" rating in a research report on Monday, September 29th. Finally, LADENBURG THALM/SH SH cut Artivion from a "buy" rating to a "neutral" rating and lifted their target price for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $43.97.

Insider Transactions at Artivion

In other Artivion news, CEO James P. Mackin sold 12,500 shares of the business's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $42.32, for a total value of $529,000.00. Following the sale, the chief executive officer directly owned 852,783 shares in the company, valued at $36,089,776.56. The trade was a 1.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Jean F. Holloway sold 10,000 shares of the business's stock in a transaction on Monday, August 25th. The shares were sold at an average price of $44.37, for a total value of $443,700.00. Following the completion of the sale, the senior vice president owned 172,129 shares in the company, valued at approximately $7,637,363.73. The trade was a 5.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 74,858 shares of company stock valued at $3,250,129. Corporate insiders own 7.60% of the company's stock.

Artivion Stock Performance

Shares of Artivion stock opened at $41.55 on Thursday. The business's fifty day simple moving average is $41.83 and its 200 day simple moving average is $32.86. The firm has a market capitalization of $1.96 billion, a P/E ratio of -98.92 and a beta of 1.67. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $45.07. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.13. The business had revenue of $112.97 million for the quarter, compared to analyst estimates of $107.96 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.Artivion's revenue for the quarter was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.